TARS

Conviction 41HealthcareScan · Thu, Jun 25, 2026

Evening star

TARS$64.31-4.18%

ResistanceSupportVol 14Insider sell

Vol MA14 591.88K

Mar 26Apr 14May 1May 19Jun 8Jun 25

Tarsus Pharmaceuticals, Inc.BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.tarsusrx.com ↗

Price64.31

Change-4.18%

Gap+0.08%

Rel volume1.22×

Avg volume662.61K

Avg $ vol40.8M

SMA 2061.51

SMA 5062.63

SMA 20068.42

Price vs 50+2.68%

Price vs 200-6.01%

MA stackmixed

50/200 cross—

Supertrendup · 59.77

RSI (14)55

MACD hist0.69

MACD cross—

Stoch %K / %D53 / 75

ADX (14)19

+DI / −DI25 / 17

RSI divergence—

MACD divergence—

ATR %+4.44%

ADR %4.27%

52w high82.51

52w low38.82

From 52w high-22.06%

Above 52w low+65.65%

New 52w highNo

SqueezeOff

Bollinger width15.94%

%B0.79

Donchian pos61.61%

Donchian high69.48

Donchian low56.00

AVWAP (52w high)68.66

vs AVWAP high-6.34%

AVWAP (52w low)65.75

vs AVWAP low-2.20%

OBV trendFlat

Chaikin MF (20)-0.14

Today vs 20d1.22×

Avg vol (14d)591.88K

Avg vol (20d)662.61K

Avg $ vol (20d)40.8M

Market cap2.77B

RS 3m (vs SPY)-5.99%

RS 6m (vs SPY)-25.29%

RS line new highNo

Trend template5/8

Technical rank43.1

1 week+2.81%

1 month+5.14%

3 months-3.97%

6 months-21.56%

1 year+55.33%

YTD-20.39%

P/E-41.66

P/B7.93

P/S6.13

P/FCF-124.01

EPS-1.59

Div yield—

ROE-19.03%

ROA-11.43%

Debt/Eq0.21

Current3.74

EV/EBITDA—

Gross margin—

Net margin-14.72%

Rev growth146.71%

EPS growth42.52%

Price target95.17

Target upside48.00%

Analyst ratingBuy

Institutional110.98%

Ent. value2.74B

Revenue162.05M

Net income-6.97M

Gross profit—

Free cash flow-22.31M

IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

ExchangeNasdaq

Shares out43.02M

Employees370

ListedFri, Oct 16, 2020

Free float36.67M

Float %86.2%

Short interest5.13M

Days to cover7.4d

Short volume79.8%

Squeeze score76 / 100

Next earningsWed, Aug 5, 2026 (41d)

EPS forecast−$0.22 · 5 est

Last EPS vs est−$0.16 vs −$0.46

Last surprise+65.2% beat

Setup gradeD

Conviction41 / 100

Pattern quality—

Tech rank43.1 / 100

Group rank50 / 100

Status lane—

Setup direction—

Pattern family

Resistance—

Support—

Days since event—

Candle confirmEvening star

News sentiment—

Financials as of Tue, Mar 31, 2026 · quarterly.

Signal lifecycle

How this symbol has moved through the lanes across 16 scans — each scan is re-classified from that day's price, so gaps are days it dropped off the board entirely.

Setting up
Jun 22
1 scan
→
Breaking out now
Jun 23
1 scan

Congress activity

Disclosed STOCK Act trades in TARS

All disclosures →

No recent disclosed trades by Congress in TARS. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in TARS · 2 buys · 4 sells

Insider	Side	Shares	Value	Traded	Filed
Azamian Bobak R. President/CEO and Board Chair · Common Stock · 2026-06-17	Sell	4.58K	$281K	2026-06-17	2026-06-22
Azamian Bobak R. President/CEO and Board Chair · Common Stock · 2026-06-17	Sell	5.42K	$335K	2026-06-17	2026-06-22
CHAUDHURI BHASKAR Director · Common Stock · 2026-06-12	Exercise	2.95K	—	2026-06-12	2026-06-16
CHAUDHURI BHASKAR Director · Restricted Stock Units · 2026-06-12	Exercise	2.95K	—	2026-06-12	2026-06-16
PYOTT DAVID E I Director · Restricted Stock Units · 2026-04-24	Exercise	1.38K	$0	2026-04-24	2026-04-28
PYOTT DAVID E I Director · Common Stock · 2026-04-24	Exercise	1.38K	—	2026-04-24	2026-04-28
PYOTT DAVID E I Director · Common Stock · 2026-04-24	Other	—	—	2026-04-24	2026-04-28

SEC filings

EDGAR filings in TARS · 4 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.

Start free — 7-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.